Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06965166 · ClinicalTrials.gov registry record
Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
A clinical trial of Rectal Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT06965166: Recruiting study of Rectal Carcinoma, sponsored by Mayo Clinic.
NCT06965166 is a study of Rectal Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 120 participants, below the 31,020-participant average among 5 other Rectal Carcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06965166, a study of Rectal Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates whether images taken using a photon counting detector CT scanner (PCD-CT) can determine the growth of rectal cancer as well as, or better than, MRI for the management of patients with rectal cancer.
Primary Outcome
Images from contrast-enhanced pelvic PCD-CT for circumferential resection margin (CRM) involvement will be compared to rectal cancer MRI images. A single-group design will be used to test whether the proportion is non-inferior, with a noninferiority difference (P0 - PB) of -0.1 (H0: P ≤ P0 versus H1: P \> P0). The comparison will be made using a one-sided, one-sample exact binomial test, with a Type I error rate (alpha) of 0.05. The limit of non-inferiority will be set at -0.10, meaning that the
Conditions Studied
Interventions
- PROCEDURE PCD-CT
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2026-12-31 |
What NCT06965166 shows while recruiting
NCT06965166 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 31,020-participant average among 5 other Rectal Carcinoma trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Rectal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which PCD-CT is the first listed.
NCT06965166 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06965166 about?
NCT06965166 is a clinical study titled "Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer". This study evaluates whether images taken using a photon counting detector CT scanner (PCD-CT) can determine the growth of rectal cancer as well as, or better than, MRI for the management of patients with rectal cancer.
What is the current status of trial NCT06965166?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2024-10-07. Estimated completion is 2026-12-31.
What conditions does trial NCT06965166 study?
This clinical trial studies the following conditions: Rectal Carcinoma.
What interventions are being tested in trial NCT06965166?
The interventions under investigation include: PCD-CT (PROCEDURE).
Who is sponsoring clinical trial NCT06965166?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06965166 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
RECRUITING · NA
-
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
RECRUITING · Phase 2
-
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
ACTIVE NOT RECRUITING · NA
-
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
ACTIVE NOT RECRUITING
-
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI